WP
AERI

Woodline Partners’s Aerie Pharmaceuticals AERI Stock Holding History

Woodline Partners’s Portfolio AERI Stock Details AERI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-419,140
Closed -$6.71M – 778
2021
Q2 		$6.71M Sell
419,140
-1,737,899
-81% -$29.8M 0.13% 189
2021
Q1 		$38.5M Buy
+2,157,039
New +$37.3M 0.86% 29

Other funds holding AERI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.32B AUM 28.11% 1-Year Est. Return

Woodline Partners's AERI Position: Q3 2021 in Review

Woodline Partners sold out of Aerie Pharmaceuticals (AERI) in Q3 2021, closing a stake of 419,140 shares — an estimated $6.71M sold.

Woodline Partners first reported a position in AERI in Q1 2021 and held it in 2 quarters. The position peaked at $38.5M in Q1 2021. 137 funds tracked by Wall St. Rank hold AERI as of Q3 2021.

  • Woodline Partners reported no remaining Aerie Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Woodline Partners sold 419,140 Aerie Pharmaceuticals shares in Q3 2021, an estimated $6.71M.
  • Woodline Partners first reported a position in Aerie Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • Woodline Partners's Aerie Pharmaceuticals position peaked at $38.5M in Q1 2021.
  • 137 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q3 2021.

Based on Woodline Partners's 13F filing for Q3 2021, filed 15 Nov 2021.